Arcus Biosciences RCUS anti-CD39 — Royalty expense

Similar metrics at other companies

TWIConsumer — Royalty expense

$476K-1.2%

TWIAgriculture — Royalty expense

$1.55M-4.1%

TWIEarthmoving/Construction — Royalty expense

$384K+10.7%

TVTXReportable Segment — Royalty expense

$24.82M+99.7%

INVADurlobactam — Royalty Expense

$0—

INVAGiapreza — Royalty Expense

$1.4M+27.3%

FAQ

What is Arcus Biosciences's anti-cd39 — royalty expense?

Arcus Biosciences (RCUS) reported anti-cd39 — royalty expense of $0 in Q4 2025.

What does anti-cd39 — royalty expense mean?

This metric represents the ongoing costs paid to third-party licensors or partners based on the commercial success or sales of anti-CD39 products. It reflects the long-term financial obligation associated with the intellectual property rights used in the development and sale of the therapy. Higher royalty expenses generally indicate successful commercialization but also represent a recurring reduction in net product margins.